On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

Abu Dhabi, UAE — The use of a balloon guide catheter was associated with worse functional outcomes than the use of a conventional guide catheter in stroke patients with large vessel anterior ...

Boston Scientific Corporation (NYSE ... Recently, we received USA approval of the FARAWAVE NAV Catheter, which combined with ...

A collection of stories from our ongoing series, Field Guide to Boston. The series at wbur.org/fieldguide offers guides and public service journalism focused on how ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings ... Recently, we received USA approval of the FARAWAVE NAV Catheter, which combined with a FARAVIEW Software to ...

Boston Scientific (NYSE:BSX) shares were down 5% in morning trading Wednesday following news that the company has paused a study for its new FARAPULSE Pulse Field Ablation system due to unforeseen ...

Boston Scientific is keeping the ball rolling in ... the company received an FDA approval for the upgraded Farapulse Nav catheter, which incorporates magnetic navigation and connects with heart ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...